Timothy J. Scannell
Known title: DirectorCIK: 0001451533
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Insulet Sets Q3 2026 Earnings Date for Nov 4. Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.
Transaction History
| NVCR | ▲ Buy | Grant | 11,610 | $0 | 6/3/2026 | View on chart |
| NVCR | ▼ Sell | Open Market | 2,945 | $46K | 6/2/2026 | View on chart |
| PODD | ▲ Buy | Grant | 1,660 | $0 | 5/20/2026 | View on chart |
| NVCR | ▲ Buy | Grant | 11,215 | $0 | 6/4/2025 | View on chart |
| NVCR | ▼ Sell | Open Market | 999 | $17K | 6/3/2025 | View on chart |
| PODD | ▲ Buy | Grant | 778 | $0 | 5/22/2025 | View on chart |
| PODD | ▼ Sell | Open Market | 5,000 | $1.1M | 9/10/2024 | View on chart |
| PODD | ▼ Sell | Open Market | 7,000 | $1.3M | 6/10/2024 | View on chart |
| NVCR | ▲ Buy | Grant | 4,053 | $0 | 6/5/2024 | View on chart |
| NVCR | ▼ Sell | Open Market | 964 | $23K | 6/4/2024 | View on chart |
| PODD | ▲ Buy | Option Exercise | 3,587 | $146K | 5/28/2024 | View on chart |
| PODD | ▼ Sell | Open Market | 3,300 | $597K | 5/28/2024 | View on chart |
| PODD | ▲ Buy | Option Exercise | 3,920 | $143K | 5/28/2024 | View on chart |
| PODD | ▲ Buy | Option Exercise | 5,525 | $151K | 5/28/2024 | View on chart |
| PODD | ▲ Buy | Option Exercise | 5,235 | $151K | 5/28/2024 | View on chart |
| PODD | ▲ Buy | Grant | 1,380 | $0 | 5/22/2024 | View on chart |
| NVCR | ▲ Buy | Grant | 3,853 | $0 | 6/7/2023 | View on chart |
| PODD | ▲ Buy | Grant | 843 | $0 | 5/23/2023 | View on chart |
| PODD | ▲ Buy | Grant | 1,009 | $0 | 5/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer
NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer. NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.